The board of the directors of The United Laboratories International Holdings Limited announced that the shareholders of the company and the potential investors that, based on the unaudited consolidated management accounts of the company for the six months ended 30 June 2017 prepared in accordance with Hong Kong Financial Reporting Standards, the Group's unaudited interim results for the six months ended 30 June 2017 is expected to record a profit of approximately RMB 100,000,000, while the loss for the six months ended 30 June 2016 is approximately RMB 13,000,000. Turning from loss to profit is mainly attributable to increase in sales of intermediate and bulk medicine products; the utilization of production capacity of the Inner Mongolia plant increased resulting in reduction of production cost. Segmental results of intermediate and bulk medicine products are substantially improved as compared with same period last year; increase in gain on fair value change of embedded derivative components of convertible bonds; and the loss on fair value change on investment properties being offset.